Robert S. Couch, MD
Disclosures: I/we have no financial relationships to report.

Name:   Robert Steven Couch, MD

Position:  Director of Developmental Pediatrics and Attending Physician, The Children’s Center Rehabilitation Hospital, Bethany, OK

Education: BA (biology) Austin College, Sherman TX  5/1978

MD  Baylor College of Medicine, Houston, TX  6/1982

Residency in Pediatrics, Baylor Affiliated Hospitals, Houston, TX 7/1982-6/1985

Fellowship, Developmental Disabilities, Kennedy-Kreiger Institute, Baltimore, MD  7/1985-6/1988

American Board of Pediatrics Certifications:

              General Pediatrics, 1988

              Neurodevelopmental Pediatrics, 2001

              Developmental and Behavioral Pediatrics, 2002

Positions:  Assistant professor of Pediatrics, The Pennsylvania State University/ Attending physician, The Milton S. Hershey Medical Center and University Hospital Rehabilitation Center, Hershey PA   8/1988 – 6/1993.

Assistant professor of Pediatrics, Vanderbilt University Medical Center, Nashville, TN  8/1993-7/2014.

Associate professor of Clinical Pediatrics, Vanderbilt University Medicine Center, Nashville, TN  8/2014-7/2015.

Clinical Assistant Professor, University of Tennessee Health Science Center, Memphis, TN   4/2008-6/2012.

Associate Medical director for Pediatric Rehabilitation, Vanderbilt Stallworth Rehabilitation Hospital, Nashville, TN 8/1993-8/2013.

Director, Developmental Pediatrics, The Children’s Center Rehabilitation Hospital, Bethany, OK  9/2015-present.

Program Director, Fellowship in Developmental and Behavioral Pediatrics, Vanderbilt University Medical Center, Nashville, TN.  2001-2003, 2009-2011, 2014-2015.


LEND faculty, Vanderbilt University Medical Center, 2009-2015.

Member, Communications Committee of the American Academy of Cerebral Palsy and Developmental Medicine 2014-present; Chairman 2017-2018, Newsletter editor 2017-present.A Prospective, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Effectiveness of Intranasal Carbetocin in Subjects with Prader Willi Syndrome (PWS) (PI)              Ferring International Pharmascience, Inc. 2013-2014

Study to Assess the Safety of 3mg/mL Gablofen(baclofen injection) Delivered by Intrathecal Administration Using the SynchromedII Programmable Infusion System. (PI) CNS Therapeutics, Inc. (Now Mallinckrodt Pharmaceuticals, Inc.)  2012-2015

Randomized, Double-Blind, Placebo Controlled, Phase 3 Trial of ZGN-440 (Subcutaneous               Beloranib in Suspension) in Obese Subjects with Prader-Willi Syndrome to Evaluate Total Body Fat Mass, Food-related Behavior, and Safety Over 6 Months. (PI)  Zafgen, Inc.    2014-2015             

A Phase IV, Prospective, Observational, Multicentre Study Evaluating the Effectiveness and Safety of Dysport®(AbobotulinumtoxinA) in Paediatric Lower Limb Spasticity.  (PI)  Ipsen Biopharmaceuticals, Inc.  2017-present.